Literature DB >> 1262966

Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. II. Particles.

J G McAfee, M L Thakur.   

Abstract

When various radioactive particles are incubated and tumbled in concentrated suspensions of blood phagocytes at body temperature for 1 hr, they bind to the phagocytic cells with a labeling yield of 30-40%. In vitro experiments show that, for some radioactive colloids, a sizeable fraction of the total cellular binding results from nonspecific surface adsorption to other cells and from reversible surface adsorption to phagocytes without engulfment. No completely satisfactory in vitro methods have been found for separating leukocytes with completely engulfed particles from those with surface-adherent particles; nonetheless, surface adherence can be partially reversed by 20% acid citrate dextrose (ACD) solution or by an excess of nonradioactive colloid. Gelatinization of colloidal particles tends to increase their binding to phagocytic cells but also increases the degree of nonspecific adherence to other cells. Technetium-99m-millimicrospheres, 0.5-2 mum in diameter, are optimal in size for phagocytosis by neutrophils, and their non-specific adherence to other cells is minimal. Because of the microspheres' poor stability in aqueous suspension, however, it is technically difficult to separate free from phagocytosed radioactivity after cell incubation. The highly stable small-particle colloids (less than 0.1 mum), such as 198Au-colloid or 111In-colloid without iron carrier, are phagocytosed poorly or not at all by neutrophils, although they are engulfed by mononuclear cells.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1262966

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

Review 1.  Occult sepsis: fate or challenge?

Authors:  J T Locher
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

2.  Isolation and labelling of human leukocytes with 99mTc.

Authors:  H Kelbaek
Journal:  Eur J Nucl Med       Date:  1986

3.  The application of radioactive labeled leucocytes for the proof of inflammations.

Authors:  H J Schroth; K P Müller; R Berberich; E Oberhausen; H Wilhelm
Journal:  Eur J Nucl Med       Date:  1979-10

Review 4.  Radiotracers used for the scintigraphic detection of infection and inflammation.

Authors:  Chris Tsopelas
Journal:  ScientificWorldJournal       Date:  2015-02-08

5.  (99m)Tc-MORF oligomers specific for bacterial ribosomal RNA as potential specific infection imaging agents.

Authors:  Ling Chen; Yi Wang; Dengfeng Cheng; Xinrong Liu; Shuping Dou; Guozheng Liu; Donald J Hnatowich; Mary Rusckowski
Journal:  Bioorg Med Chem       Date:  2013-08-28       Impact factor: 3.641

6.  Labelling of leucocytes with colloidal technetium-99m-SnF2: an investigation of the labelling process by autoradiography.

Authors:  M R Puncher; P J Blower
Journal:  Eur J Nucl Med       Date:  1995-02

7.  Leucocyte scanning: preparation and labelling of leucocytes with 111-Indium oxide and its clinical application.

Authors:  A Laue; U Heinken; D Schulz-Heinken; H Hundeshagen
Journal:  Eur J Nucl Med       Date:  1984

8.  Identification of factors affecting technetium 99m leucocyte labelling by phagocytic engulfment and development of an optimal technique.

Authors:  R W Hanna; F E Lomas
Journal:  Eur J Nucl Med       Date:  1986

Review 9.  Recent trends in soft-tissue infection imaging.

Authors:  Nicholas Petruzzi; Nylla Shanthly; Mathew Thakur
Journal:  Semin Nucl Med       Date:  2009-03       Impact factor: 4.446

10.  Biodistribution of the radionuclides (18)F-FDG, (11)C-methionine, (11)C-PK11195, and (68)Ga-citrate in domestic juvenile female pigs and morphological and molecular imaging of the tracers in hematogenously disseminated Staphylococcus aureus lesions.

Authors:  Pia Afzelius; Ole L Nielsen; Aage Ko Alstrup; Dirk Bender; Páll S Leifsson; Svend B Jensen; Henrik C Schønheyder
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.